FOLFOX 4→DCF方案一线治疗晚期胃癌的临床观察

目的探讨FOLFOX4→DCF方案治疗晚期胃癌的疗效和安全性。方法25例晚期胃癌患者先采用FOLFOX4方案化疗,14天为1个周期,治疗3个周期。FOLFOX4方案化疗3个周期结束后第14天开始给予DCF方案化疗,21天为1个周期,治疗3个周期。结果第15周复查显示：完全缓解（CR）4例（16%）,部分缓解（PR）11例（44%）,稳定（SD）6例（24%）,进展（PD）4例（16%）,总有效率（CR＋PR）为60%（15/25）,疾病控制率84%（21/25）。中位疾病进展时间（TTP）为7.8个月（95%可信区间,3.8～12.2个月）,中位生存期（MST）为11.7个月（95%可信区间,5.8～16.7个月）,1年生存率为44%（11/25）。毒性反应主要是中性粒细胞减少。结论FOLFOX4→DCF方案治疗晚期胃癌具有较好的疗效和安全性。

FOLFOX 4 Followed by DCF as First-line Regimens for Advanced Gastric Cancer

Objective To evaluate the efficacy and safety of FOLFOX 4→DCF regimen in patients with advanced gastric cancer. Methods we enrolled 25 advanced gastric cancer patients ,who received FOLFOX 4 regimen first. 14 days per cycle, for 3 cycles. Then, the patients received DCF regimen after 3 cycles for FOLFOX 4 regimen. 21 days per cycle ,for 3 cycles. Results The patients were examined after 15 weeks. There were 4 cases CR （ 16% ） and 11 cases PR （44%） ,6 cases SD （24%） and 4 cases PD （ 16% ）. Overall response rate （CR ＋ PR） was 60% （15/25）. Disease control rate was 84% （21/25）. The median time to progression was 7.8 months （95% CI,3.8 - 12.2 months） ,the median survival time was 11.7 months （95% CI,5.8 - 16.7 months）. One-year survival rate was 44% （ 11/25 ）. The main side effect was neutropenia. Conclusion FOLFOX 4→DCF regimen is feasible and effective for treatment in patients with advanced gastric cancer.